Company at a Glance
EnzySurge Ltd is a developer and provider of innovative products for the treatment and management of chronic wounds (diabetic foot, pressure and venous ulcers), for the outpatient and home care markets. The company’s vision is offer a comprehensive solution that improves the quality of life for chronic-wound patients by shortening healing time, preventing hospitalization and reducing labor and treatment costs.
The FDA-cleared DermaStream® platform is a new modality of wound care that creates a closed, moist environment to facilitate the normal wound healing process, through Continuous Streaming Therapy
(CST™ ).CST is the continuous streaming of fresh therapeutic solutions to a controlled wound bed, while simultaneously removing exudates and infectious materials. The CST mode of action produces negative pressure above the wound without the need for external equipment. This combined effect allows the DermaStream platform to be a comprehensive approach to wound management.
The company’s headquarters and R&D center are located in Israel. U.S. headquarters, sales and marketing office are located in Richmond, VA.
Technology & Product(s)
User’s friendly and easy-to-use, the DermaStream product line is suitable for use in any setting of care – from inpatient to outpatient and home care.
DermaStream
- Single patient use, disposable device
- Enables continuous streaming of therapeutic solutions
- Provides closed, moist environment for comprehensive wound care
- Produces gravity-based negative pressure above the wound bed
- Low cost and user’s friendly
SilverStream Wound Management Solution
- Kills MRSA and multi-drug resistant bacteria
- Protects wound from contaminations and sooths pain
- Cleanses and moisturizes wound and eliminates odors
- Enhances tissue regeneration and wound closure
EnzyStream Wound Debridement Solution
- Unique proteolytic enzymatic agent formulation that selectively removes necrotic tissues and fibrin
- Safety and preliminary efficacy recently demonstrated in a multi-centered, placebo-controlled, double blind study on 48 patients
Goal
Objectives: European distribution partners, strategic alliances
Target Countries: Germany, UK, France, Italy